<DOC>
	<DOCNO>NCT02232594</DOCNO>
	<brief_summary>The aim postmarketing surveillance obtain information tolerability efficacy Berodual速 metered-dose inhaler treatment chronic obstructive respiratory tract disease condition daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study Berodual速 Metered-dose Inhaler Chronic Obstructive Respiratory Tract Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Patients either sex 40 year symptoms chronic obstructive airway disease Only patient treat Berodual速 within last year include Contraindications list Instructions Use/Summary Product Characteristics Berodual速 metereddose inhaler</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>